StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)

Close on Nov 17, 2026Market cap $654.78MP/E –Yield –

Janux Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Janux Therapeutics's price to sales ratio was 31.5× on Nov 11, 2026, against 205.0× a year earlier. Over the last 5 years it ranged from 31.5× to 401.9×, with a median of 95.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202631.5×−51.4
2025Dec 31, 202583.0×−131.8
2024Dec 31, 2024214.7×+156.3
2023Dec 29, 202358.5×−15.6
2022Dec 30, 202274.1×−327.8
2021Dec 31, 2021401.9×–

More Janux Therapeutics figures

See a number that looks wrong?